Biotia Closes $9M to Expand Infectious Disease Diagnostics
Biotia closed $9M Series A to scale its infectious disease diagnostics business, expanding into women's health and orthopedic markets.
The big picture: Biotia has closed an oversubscribed $9 million financing to expand its infectious disease diagnostics business. The company plans to scale its New York City laboratory, develop additional women’s health tests, and enter the orthopedic diagnostics market.
Why it matters:
- Addressing complex infections: Biotia’s pathogen genomics and AI target chronic and complex infections often missed by conventional methods, improving diagnostic accuracy.
- Expanding market reach: The capital allows Biotia to move beyond its initial UTI focus into broader women’s health and orthopedic diagnostics, addressing significant unmet needs.
- Strategic leadership: New board and advisory members bring expertise in healthcare delivery, clinical practice, and commercialization to support the company’s growth.
How it works:
- Pathogen genomics & AI: Biotia employs clinical metagenomics to analyze genetic material from samples, identifying microorganisms linked to infections.
- High-complexity lab: The company operates a CLIA-certified diagnostic laboratory in New York City, ensuring regulatory compliance and high-quality testing.
- Flagship product: The BIOTIA-ID Urine Test offers 97% sensitivity and 99% specificity for recurrent and complicated urinary tract infections, available across all 50 states.
The catch: The highly competitive diagnostics market requires significant investment in R&D and commercialization. Securing broad reimbursement for novel metagenomics tests can be challenging, and expanding into new clinical areas like women’s health and orthopedics will necessitate tailored validation and market adoption strategies.
Key Facts
- Company: Biotia
- Amount: $9M
- Round: Series A
- Investors: Convergent Ventures, DigitalDx Ventures, Cloquet Capital Partners, Continuum Health Ventures, I-Lab Angels, EGB Capital, Leawood Venture Capital, Red Bear Angels, Red Bear Ventures, Tim Barry, Dr. Clive Fields
- Founders: Niamh O’Hara, Chris Mason
- Sector: Infectious Disease Diagnostics
- Headquarters: New York City, US
Funding Weekly
Every AI funding round we reported last week: the totals, the biggest deals and what they add up to. Weekly · Tuesdays.